GleamWall
中文EN

GMAB GENMAB A/S IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1434265

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY19.2%
TTM net income YoY-15.0%
TTM EPS YoY-12.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin93.6%
Operating margin28.6%
Net margin25.9%
FCF margin30.9%
EBITDA margin—

Returns

ROE17.5%
ROA10.0%
ROIC (approx.)12.9%
Asset turnover0.39x

Leverage & solvency

Liabilities / assets54.6%
Debt / equity0.90x
Current ratio2.02x
Interest coverage3.96x

Cash quality & payout

Operating cash flow / net income1.23x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q2*2025-06-30 · USD2024Q2*2024-06-30 · DKK2023Q2*2023-06-30 · DKK2022Q2*2022-06-30 · DKK2021Q2*2021-06-30 · DKK2020Q2*2020-06-30 · DKK2019Q2*2019-06-30 · DKK2018Q2*2018-06-30 · DKK
Income statement
Revenue$925.00M5.40B4.17B3.16B1.97B5.45B774.00M509.68M
Cost of revenue$57.00M190.00M21.00M—————
Gross profit$868.00M5.21B4.15B—————
R&D expense$364.00M2.50B1.85B1.28B921.00M775.00M564.00M318.89M
SG&A expense$144.00M894.00M827.00M633.00M264.00M179.00M73.00M55.74M
Operating income$360.00M1.64B1.47B1.25B787.00M4.50B137.00M135.04M
Interest expense$91.00M399.00M120.00M200.00M430.00M211.00M60.00M—
Pretax income$423.00M2.13B1.69B2.49B422.00M4.33B111.00M335.31M
Income tax$87.00M719.00M359.00M598.00M116.00M950.00M26.00M74.79M
Net income$336.00M1.41B1.33B1.89B306.00M3.38B85.00M260.53M
EPS (basic)5.4421.8520.4628.874.6851.881.384.26
EPS (diluted)5.4221.7020.2828.664.6451.351.354.21
Balance sheet
Cash & equivalents$1.30B4.33B10.87B9.82B9.48B6.61B583.00M1.09B
Receivables$998.00M6.17B4.69B3.88B2.43B6.36B859.91M—
Inventory$13.00M36.00M51.00M—————
Current assets$3.91B21.94B29.75B25.49B20.30B19.14B7.81B—
PP&E, netmay include right-of-use assets (IFRS)$152.00M952.00M908.00M684.00M535.00M414.00M175.95M—
Goodwill$355.00M2.52B——————
Intangibles$1.75B12.01B129.00M216.00M297.00M413.00M421.43M—
Total assets$6.46B38.62B31.98B27.48B22.48B20.68B8.98B—
Current liabilities$629.00M4.36B1.99B1.94B1.35B2.01B524.56M—
Total liabilities$1.16B7.65B3.22B2.99B2.23B2.81B690.80M—
Shareholders' equity$5.30B30.97B28.56B24.48B20.25B17.87B8.29B6.86B
Cash flow statement
Operating cash flow————————

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.